Guanfacine Hydrochloride, AREA[OverallStatus], Open or Pending: 17 Clinical Trials, Page 1 of 2

1 2

Include Studies Not Open or Pending

6

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

Condition(s):Prader-Willi Syndrome; Aggression; Self-Injurious Behavior; Pathologic Processes; Behavioral Symptoms; Intellectual Disability; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Abnormalities, Multiple; Congenital Abnormalities; Chromosome Disorders; Genetic Diseases, Inborn; Obesity; Overnutrition; Nutrition Disorders; Antihypertensive Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Physiological Effects of Drugs; Skin-PickingLast Updated:March 15, 2023Recruiting

1 2

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.